Study S001551

Post-Marketing Surveillance Study: 12 To 24 Weeks Study On The Treatment Emergent Adverse Events In Patients With Type 2 Diabetes Taking Exenatide In Korea

Name: LivingGLP1 adjudicated trial data and network meta-analysis results
Creator: Ahmad Sofi-Mahmudi
License: https://creativecommons.org/licenses/by/4.0/

ClinicalTrials.gov record

Registration

Registration: NCT02090673
Study type: OBSERVATIONAL
Status: COMPLETED
Enrollment: 1711
Start: 2009-02
Primary completion: 2014-03
Lead sponsor: AstraZeneca
Conditions: Diabetes Mellitus Type 2
Interventions: DRUG:Exenatide
Results posted: FALSE

Registered primary outcomes

The proportion of treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs) in patients who are treated with Exenatide for type 2 diabetes mellitus [At 12 weeks ± 4 weeks or 24 weeks ± 4 weeks]

Linked records (1)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.

Record	Title	Year	Design	Identifiers	Link basis
R0024962	Effectiveness and safety of exenatide in Korean patients with type 2 diabetes inadequately controlled with oral hypoglycemic agents: an observational study in a real clinical practice. Hwang YC, BMC endocrine disorders	2017	Randomized trial	PMID 29065865 DOI	cites ClinicalTrials.gov:NCT02090673; registry reference DERIVED:29065865